Search

Your search keyword '"Guolo, Fabio"' showing total 7 results
Start Over Author "Guolo, Fabio" Publication Type Electronic Resources
7 results on '"Guolo, Fabio"'

1. Optimal Duration of CPX-351 Treatment and Best Timing for Consolidation with Allogeneic Stem Cell Transplantation: Evidence from a Large Real-World Italian Study

Author

Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, Todisco, Elisabetta, Guolo, F, Fianchi, L, Martelli, M, Chiusolo, P, Lussana, F, Grimaldi, F, Pilo, F, Rondoni, M, Fili, C, Capelli, D, Breccia, M, Mastaglio, S, Bocchia, M, Fumagalli, M, Galimberti, S, Mancini, V, Piccioni, A, Maurillo, L, Palmieri, R, Corbingi, A, Vetro, C, Sperotto, A, Gigli, F, Zappasodi, P, Mulé, A, Borlenghi, E, Dargenio, M, Lessi, F, Cerrano, M, Isidori, A, Brunetti, L, Papayannidis, C, Lunghi, M, Alati, C, Gatani, S, Mannelli, F, Fracchiolla, N, Gottardi, M, Cairoli, R, Ferrara, F, Lemoli, R, Venditti, A, Pagano, L, Todisco, E, Guolo, Fabio, Fianchi, Luana, Martelli, Maria Paola, Chiusolo, Patrizia, Lussana, Federico, Grimaldi, Francesco, Pilo, Federica, Rondoni, Michela, Fili, Carla, Capelli, Debora, Breccia, Massimo, Mastaglio, Sara, Bocchia, Monica, Fumagalli, Monica, Galimberti, Sara, Mancini, Valentina, Piccioni, Anna Lina, Maurillo, Luca, Palmieri, Raffaele, Corbingi, Andrea, Vetro, Calogero, Sperotto, Alessandra, Gigli, Federica, Zappasodi, Patrizia, Mulé, Antonio, Borlenghi, Erika, Dargenio, Michelina, Lessi, Federica, Cerrano, Marco, Isidori, Alessandro, Brunetti, Lorenzo, Papayannidis, Cristina, Lunghi, Monia, Alati, Caterina, Gatani, Samuele, Mannelli, Francesco, Fracchiolla, Nicola, Gottardi, Michele, Cairoli, Roberto, Ferrara, Felicetto, Lemoli, Roberto Massimo, Venditti, Adriano, Pagano, Livio, and Todisco, Elisabetta

Published
2023

2. Full donor chimerism after allogeneic hematopoietic stem cells transplant for myelofibrosis: The role of the conditioning regimen

Author

Chiusolo, Patrizia, Bregante, Stefania, Giammarco, Sabrina, Lamparelli, Teresa, Casarino, Lucia, Dominietto, Alida, Raiola Anna, Maria, Metafuni, Elisabetta, Di Grazia, Carmen, Gualandi, Francesca, Sora', Federica, Laurenti, Luca, Sica, Simona, Barosi, Gianni, Guolo, Fabio, Rossi, Monica, Rossi, Elena, Vannucchi, Alessandro, Signori, Alessio, De Stefano, Valerio, Bacigalupo, Andrea, Angelucci, Emanuele, Chiusolo Patrizia (ORCID:0000-0002-1355-1587), Metafuni Elisabetta, Sora Federica (ORCID:0000-0002-9607-5298), Laurenti Luca (ORCID:0000-0002-8327-1396), Sica Simona (ORCID:0000-0003-2426-3465), Rossi Monica, Rossi Elena (ORCID:0000-0002-7572-9379), De Stefano Valerio (ORCID:0000-0002-5178-5827), Bacigalupo Andrea (ORCID:0000-0002-9119-567X), Chiusolo, Patrizia, Bregante, Stefania, Giammarco, Sabrina, Lamparelli, Teresa, Casarino, Lucia, Dominietto, Alida, Raiola Anna, Maria, Metafuni, Elisabetta, Di Grazia, Carmen, Gualandi, Francesca, Sora', Federica, Laurenti, Luca, Sica, Simona, Barosi, Gianni, Guolo, Fabio, Rossi, Monica, Rossi, Elena, Vannucchi, Alessandro, Signori, Alessio, De Stefano, Valerio, Bacigalupo, Andrea, Angelucci, Emanuele, Chiusolo Patrizia (ORCID:0000-0002-1355-1587), Metafuni Elisabetta, Sora Federica (ORCID:0000-0002-9607-5298), Laurenti Luca (ORCID:0000-0002-8327-1396), Sica Simona (ORCID:0000-0003-2426-3465), Rossi Monica, Rossi Elena (ORCID:0000-0002-7572-9379), De Stefano Valerio (ORCID:0000-0002-5178-5827), and Bacigalupo Andrea (ORCID:0000-0002-9119-567X)

Abstract

The aim of this retrospective study was to assess the rate of full donor chimerism (F-DC) in patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two alkylating agents. We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30. There were two groups: 42 patients were conditioned with one alkylating agent (ONE-ALK), either thiotepa or busulfan or melphalan, in combination with fludarabine, whereas 78 patients were prepared with two alkylating agents, thiotepa busulfan and fludarabine (TBF). Patients receiving TBF were older (57 vs 52 years), were less frequently splenectomized pre-HSCT (31% vs 59%), had more frequently intermediate-2/high DIPSS scores (90% vs 74%), were grafted more frequently from alternative donors (83% vs 33%) and received more frequently ruxolitinib pre-HSCT (26% vs 7%). The proportion of patients with F-DC on day +30, in the TBF vs the ONE-ALK group, was respectively 87% vs 45% (P < .001). The 5-year cumulative incidence of relapse was 9% in the TBF group, vs 43% for the ONE-ALK group (P < .001). The 5-year actuarial disease-free survival was 63% for TBF and 38% for the ONE-ALK group (P = .004). In conclusion, early full donor chimerism is a prerequisite for long term control of disease in patients with myelofibrosis, undergoing an allogeneic HSCT. The combination of two alkylating agents in the conditioning regimen, provides a higher chance of achieving full donor chimerism on day+30, and thus a higher chance of long term disease free survival.

Published
2021

3. full donor chimerism after allogenic hematopoietic stem cells transplant for myelofibrosis the role of the conditioning regiment

Author

Chiusolo, Patrizia, Bregante, Stefania, Giammarco, Sabrina, Lamparelli, Teresa, Casarino, Lucia, Dominietto, Alida, Raiola, Anna Maria, Metafuni, Elisabetta, Di Grazia, Carmen, Gualandi, Francesca, Sora', Federica, Laurenti, Luca, Sica, Simona, Barosi, Gianni, Guolo, Fabio, Rossi, Monica, Rossi, Elena, Vannucchi, Alessandro, Signori, Alessio, De Stefano, Valerio, Bacigalupo, Andrea, Angelucci, Emanuele, Patrizia, Chiusolo (ORCID:0000-0002-1355-1587), Elisabetta, Metafuni, Federica, Sora (ORCID:0000-0002-9607-5298), Luca, Laurenti (ORCID:0000-0002-8327-1396), Simona, Sica (ORCID:0000-0003-2426-3465), Monica, Rossi, Elena, Rossi (ORCID:0000-0002-7572-9379), Valerio, De Stefano (ORCID:0000-0002-5178-5827), Andrea, Bacigalupo (ORCID:0000-0002-9119-567X), Chiusolo, Patrizia, Bregante, Stefania, Giammarco, Sabrina, Lamparelli, Teresa, Casarino, Lucia, Dominietto, Alida, Raiola, Anna Maria, Metafuni, Elisabetta, Di Grazia, Carmen, Gualandi, Francesca, Sora', Federica, Laurenti, Luca, Sica, Simona, Barosi, Gianni, Guolo, Fabio, Rossi, Monica, Rossi, Elena, Vannucchi, Alessandro, Signori, Alessio, De Stefano, Valerio, Bacigalupo, Andrea, Angelucci, Emanuele, Patrizia, Chiusolo (ORCID:0000-0002-1355-1587), Elisabetta, Metafuni, Federica, Sora (ORCID:0000-0002-9607-5298), Luca, Laurenti (ORCID:0000-0002-8327-1396), Simona, Sica (ORCID:0000-0003-2426-3465), Monica, Rossi, Elena, Rossi (ORCID:0000-0002-7572-9379), Valerio, De Stefano (ORCID:0000-0002-5178-5827), and Andrea, Bacigalupo (ORCID:0000-0002-9119-567X)

Abstract

The aim of this retrospective study was to assess the rate of full donor chimerism (F‐DC) in patients with myelofibrosis, prepared for an allogeneic stem cell transplant, with one or two alkylating agents. We analyzed 120 patients with myelofibrosis, for whom chimerism data were available on day +30. There were two groups: 42 patients were conditioned with one alkylating agent (ONE‐ALK), either thiotepa or busulfan or melphalan, in combination with fludarabine, whereas 78 patients were prepared with two alkylating agents, thiotepa busulfan and fludarabine (TBF). Patients receiving TBF were older (57 vs 52 years), were less frequently splenectomized pre‐HSCT (31% vs 59%), had more frequently intermediate‐2/high DIPSS scores (90% vs 74%), were grafted more frequently from alternative donors (83% vs 33%) and received more frequently ruxolitinib pre‐HSCT (26% vs 7%). The proportion of patients with F‐DC on day +30, in the TBF vs the ONE‐ALK group, was respectively 87% vs 45% (P < .001). The 5‐year cumulative incidence of relapse was 9% in the TBF group, vs 43% for the ONE‐ALK group (P < .001). The 5‐year actuarial disease‐free survival was 63% for TBF and 38% for the ONE‐ALK group (P = .004). In conclusion, early full donor chimerism is a prerequisite for long term control of disease in patients with myelofibrosis, undergoing an allogeneic HSCT. The combination of two alkylating agents in the conditioning regimen, provides a higher chance of achieving full donor chimerism on day+30, and thus a higher chance of long term disease free survival.

Published
2021

4. CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program

Author

Guolo, Fabio, Fianchi, Luana, Minetto, Paola, Clavio, Marino, Gottardi, Michele, Galimberti, Sara, Rizzuto, Giuliana, Rondoni, Michela, Bertani, Giambattista, Dargenio, Michela, Bilio, Atto, Scappini, Barbara, Zappasodi, Patrizia, Scattolin, Anna Maria, Grimaldi, Francesco, Pietrantuono, Giuseppe, Musto, Pellegrino, Cerrano, Marco, D'Ardia, Stefano, Audisio, Ernesta, Cignetti, Alessandro, Pasciolla, Crescenza, Pavesi, Francesca, Candoni, Anna, Gurreri, Carmela, Morselli, Monica, Alati, Caterina, Fracchiolla, Nicola, Rossi, Giovanni, Caizzi, Manuela, Carnevale-Schianca, Fabrizio, Tafuri, Agostino, Rossi, Giuseppe, Ferrara, Felicetto, Pagano, Livio, Lemoli, Roberto Massimo, Pagano, Livio (ORCID:0000-0001-8287-928X), Guolo, Fabio, Fianchi, Luana, Minetto, Paola, Clavio, Marino, Gottardi, Michele, Galimberti, Sara, Rizzuto, Giuliana, Rondoni, Michela, Bertani, Giambattista, Dargenio, Michela, Bilio, Atto, Scappini, Barbara, Zappasodi, Patrizia, Scattolin, Anna Maria, Grimaldi, Francesco, Pietrantuono, Giuseppe, Musto, Pellegrino, Cerrano, Marco, D'Ardia, Stefano, Audisio, Ernesta, Cignetti, Alessandro, Pasciolla, Crescenza, Pavesi, Francesca, Candoni, Anna, Gurreri, Carmela, Morselli, Monica, Alati, Caterina, Fracchiolla, Nicola, Rossi, Giovanni, Caizzi, Manuela, Carnevale-Schianca, Fabrizio, Tafuri, Agostino, Rossi, Giuseppe, Ferrara, Felicetto, Pagano, Livio, Lemoli, Roberto Massimo, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Secondary acute myeloid leukemia (sAML) poorly responds to conventional treatments and allogeneic stem cell transplantation (HSCT). We evaluated toxicity and efficacy of CPX-351 in 71 elderly patients (median age 66 years) with sAML enrolled in the Italian Named (Compassionate) Use Program. Sixty days treatment-related mortality was 7% (5/71). The response rate at the end of treatment was: CR/CRi in 50/71 patients (70.4%), PR in 6/71 (8.5%), and NR in 10/71 (19.7%). After a median follow-up of 11 months relapse was observed in 10/50 patients (20%) and 12 months cumulative incidence of relapse (CIR) was 23.6%. Median duration of response was not reached. In competing risk analysis, CIR was reduced when HSCT was performed in first CR (12 months CIR of 5% and 37.4%, respectively, for patients receiving (=20) or not (=30) HSCT, p = 0.012). Twelve-months OS was 68.6% (median not reached). In landmark analysis, HSCT in CR1 was the only significant predictor of longer survival (12 months OS of 100 and 70.5%, for patients undergoing or not HSCT in CR1, respectively, p = 0.011). In conclusion, we extend to a real-life setting, the notion that CPX is an effective regimen for high risk AML patients and may improve the results of HSCT.

Published
2020

5. High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients

Author

Guolo, Fabio, Minetto, Paola, Clavio, Marino, Miglino, Maurizio, Di Grazia, Carmen, Ballerini, Filippo, Pastori, Giordana, Guardo, Daniela, Colombo, Nicoletta, Kunkl, Annalisa, Fugazza, Giuseppina, Rebesco, Barbara, Sessarego, Mario, Lemoli, Roberto Massimo, Bacigalupo, Andrea, Gobbi, Marco, Bacigalupo, Andrea (ORCID:0000-0002-9119-567X), Guolo, Fabio, Minetto, Paola, Clavio, Marino, Miglino, Maurizio, Di Grazia, Carmen, Ballerini, Filippo, Pastori, Giordana, Guardo, Daniela, Colombo, Nicoletta, Kunkl, Annalisa, Fugazza, Giuseppina, Rebesco, Barbara, Sessarego, Mario, Lemoli, Roberto Massimo, Bacigalupo, Andrea, Gobbi, Marco, and Bacigalupo, Andrea (ORCID:0000-0002-9119-567X)

Abstract

About 105 consecutive acute myeloid leukemia (AML) patients treated with the same induction-consolidation program between 2004 and 2013 were retrospectively analyzed. Median age was 47 years. The first induction course included fludarabine (Flu) and high-dose cytarabine (Ara-C) plus idarubicin (Ida), with or without gemtuzumab-ozogamicin (GO) 3 mg/m2 (FLAI-5). Patients achieving complete remission (CR) received a second course without fludarabine but with higher dose of idarubicin. Patients not achieving CR received an intensified second course. Patients not scheduled for early allogeneic bone marrow transplantation (HSCT) where planned to receive at least two courses of consolidation therapy with Ara-C. Our double induction strategy significantly differs from described fludarabine-containing regimens, as patients achieving CR receive a second course without fludarabine, to avoid excess toxicity, and Ara-C consolidation is administrated at the reduced cumulative dose of 8 g/m2 per cycle. Toxicity is a major concern in fludarabine containing induction, including the recent Medical Research Council AML15 fludarabine, cytarabine, idaraubicin and G-CSF (FLAG-Ida) arm, and, despite higher anti-leukemic efficacy, only a minority of patients is able to complete the full planned program. In this article, we show that our therapeutic program is generally well tolerated, as most patients were able to receive subsequent therapy at full dose and in a timely manner, with a 30-day mortality of 4.8%. The omission of fludarabine in the second course did not reduce efficacy, as a CR rate of 83% was achieved and 3-year disease-free survival and overall survival (OS) were 49.6% and 50.9%, respectively. Our experience shows that FLAI-5/Ara-C + Ida double induction followed by risk-oriented consolidation therapy can result in good overall outcome with acceptable toxicity. Am. J. Hematol. 91:755–762, 2016. © 2016 Wiley Periodicals, Inc.

Published
2016

6. De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened 'GO question'

Author

Clavio, M, Cruciani, F, Minetto, P, Guolo, F, Ballerini, F, Marani, C, De Astis, E, Aquino, S, Bergamaschi, M, Mitscheunig, L, Grasso, R, Colombo, N, Ghiggi, C, Lovera, D, Pastori, G, Avenoso, D, Miglino, M, Gobbi, M, Clavio, Marino, Cruciani, Fabio, Minetto, Paola, Guolo, Fabio, Ballerini, Filippo, Marani, Carlo, De Astis, Enrico, Aquino, Sara, Bergamaschi, Micaela, Mitscheunig, Laura, Grasso, Raffaella, Colombo, Nicoletta, Ghiggi, Chiara, Lovera, Davide, Pastori, Giordana, Avenoso, Daniele, Miglino, Maurizio, Gobbi, Marco, Clavio, M, Cruciani, F, Minetto, P, Guolo, F, Ballerini, F, Marani, C, De Astis, E, Aquino, S, Bergamaschi, M, Mitscheunig, L, Grasso, R, Colombo, N, Ghiggi, C, Lovera, D, Pastori, G, Avenoso, D, Miglino, M, Gobbi, M, Clavio, Marino, Cruciani, Fabio, Minetto, Paola, Guolo, Fabio, Ballerini, Filippo, Marani, Carlo, De Astis, Enrico, Aquino, Sara, Bergamaschi, Micaela, Mitscheunig, Laura, Grasso, Raffaella, Colombo, Nicoletta, Ghiggi, Chiara, Lovera, Davide, Pastori, Giordana, Avenoso, Daniele, Miglino, Maurizio, and Gobbi, Marco

Abstract

We report the final results of a prospective trial testing the combination of fludarabine, Ara-C and idarubicin (FLAI) followed by low-dose gemtuzumab ozogamicin (FLAI-GO) in 85 patients aged 60 years or more with CD33+ acute myeloid leukaemia (AML). Median age was 68 years (60-82); karyotype was unfavourable in 21 patients (24 %), intermediate in 63 (74 %) and favourable in 1 (2 %). There were five therapy-related deaths. Of the 80 evaluable patients, 47 achieved complete response (CR) (58 %); CR rates were 65 and 32 % in good-intermediate/poor karyotype patients, respectively. Median length of CR was 7 months (3-76). The cumulative incidence of relapse was 84 % with an actuarial survival of 50.3 % at 1 year and 14.4 % at 2 years. The study control population is an unselected consecutive historic cohort of 104 patients treated with the FLAI regimen, who were matched for age and prognostic factors. CR rates after FLAI-GO and FLAI were comparable. However, patients with de novo AML and intermediate-favourable karyotype receiving GO had a significantly lower risk of relapse at 2 years as compared to patients not receiving GO (n = 77) (40 vs 80 %, p = 0.01) and significantly better disease-free survival (p = 0.018) and overall survival (p = 0.022).

Published
2013

7. Nucleophosmin gene-based monitoring in de novo cytogenetically normal acute myeloid leukemia with nucleophosmin gene mutations: comparison with cytofluorimetric analysis and study of Wilms tumor gene 1 expression

Author

Miglino, M, Colombo, N, Grasso, R, Marani, C, Clavio, M, Pica, G, Ballerini, F, Ghiggi, C, Minetto, P, Guolo, F, Carella, A, Gobbi, M, Miglino, Maurizio, Colombo, Nicoletta, Grasso, Raffaella, Marani, Carlo, Clavio, Marino, Pica, Gian Matteo, Ballerini, Filippo, Ghiggi, Chiara, Minetto, Paola, Guolo, Fabio, Carella, Angelo Michele, Gobbi, Marco, Miglino, M, Colombo, N, Grasso, R, Marani, C, Clavio, M, Pica, G, Ballerini, F, Ghiggi, C, Minetto, P, Guolo, F, Carella, A, Gobbi, M, Miglino, Maurizio, Colombo, Nicoletta, Grasso, Raffaella, Marani, Carlo, Clavio, Marino, Pica, Gian Matteo, Ballerini, Filippo, Ghiggi, Chiara, Minetto, Paola, Guolo, Fabio, Carella, Angelo Michele, and Gobbi, Marco

Abstract

We compared the clinical value of minimal residual disease (MRD) monitoring by cytofluorimetric methods, Wilms tumor gene 1 (WT1) expression and the study of nucleophosmin gene (NPM) mutations in a series of 26 patients with NPM-mutated de novo acute myeloid leukemia (NPM-AML) who achieved complete hematological remission after conventional chemotherapy. The relapse risk was significantly lower only in patients achieving a NPM molecular complete response (NPM mol-CR) and confirmed NPM mol-CR (non-detectable NPM mutations in two consecutive marrow samples). The disease-free survival (DFS) of patients achieving a <4-log or >= 4-log reduction in NPM value after induction therapy was 12.6 % and 50%, respectively, at 36 months (p = 0.009). The attainment of a confirmed NPM-CR had a significant influence on overall survival (OS at 36 months was 64.3% and 11.9% in patients obtaining or not obtaining confirmed NPM-CR, respectively, p < 0.03). We confirm that NPM-molecular relapse (NPM-rel) is always followed by hematological relapse (H-rel), but longitudinal studies of NPM mutations may predict an impending H-rel earlier than flow cytometric- or WT1-based methods.

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results